Leidos Secures Contract for Organ Transplant Network Modernization
Leidos announced a significant move aimed at transforming the organ transplantation landscape by securing a crucial contract. This partnership with the U.S. Department of Health and Human Services will modernize the Organ Procurement and Transplant Network (OPTN), a system essential for streamlining vital information regarding organ transplants.
The Importance of the OPTN Contract
The OPTN plays a pivotal role in matching donors with patients in need of life-saving transplants. Under this new contract, which could reach a value of $235 million, Leidos commits to modernizing key components of this crucial network. This contract, with a base year and four additional option years, allows for flexibility in addressing the evolving needs of organ transplantation.
Empowering Lives Through Technology
Liz Porter, the president of Leidos Health & Civil Sector, noted the urgency of the mission: "Every 10 minutes, someone is added to the transplant waiting list." By optimizing access to information and deploying new tools, the goal is to facilitate timely and accurate data dissemination, crucial for patients, families, and healthcare providers.
A Commitment to Continuous Improvement
Through this initiative, Leidos aims to elevate transparency, performance, governance, and efficiency across the entire organ donation and transplantation process. The effort targets the needs of over 100,000 individuals currently on the national transplant waitlist, providing them with essential resources to enhance their chances of receiving the organs they desperately need.
Leidos: A Leader in Health and Technology
Leidos is a key player in national security and healthcare, boasting a workforce of 48,000. The company's extensive expertise in technology and large-scale electronic health record implementations positions it uniquely to partner effectively with HRSA and lead the OPTN modernization effort.
Transformative Reforms Ahead
This modernization initiative marks the most significant reforms in nearly four decades for the OPTN. It seeks to not only improve health outcomes but also better serve both patients and their families. As Leidos embarks on this journey, a more efficient and responsive organ transplant system is on the horizon.
About Leidos Holdings, Inc.
Leidos is a Fortune 500 innovation company dedicated to solving the world's most pressing challenges across multiple industries. With reported annual revenues of approximately $15.4 billion, Leidos continuously strives to deliver smarter and safer technological solutions. For more information about Leidos, you can visit their official site.
Frequently Asked Questions
What contract did Leidos secure recently?
Leidos secured a contract to modernize the Organ Procurement and Transplant Network (OPTN) to enhance organ transplantation processes.
How much is the contract worth?
The contract has a potential total value of $235 million, including a base period and several option periods.
What is the role of the OPTN?
The OPTN connects organ donors with patients in need of transplants, facilitating the sharing of vital information across the healthcare community.
How will the modernization impact patients?
This modernization aims to improve transparency and efficiency, directly benefiting over 100,000 patients on the transplant waiting list.
What expertise does Leidos bring to this initiative?
Leidos brings extensive experience in technology, health systems, and electronic health records, positioning the company well for successful collaboration on this project.
